


 Cite this: *RSC Adv.*, 2024, 14, 38293

Design and synthesis of betulinic acid–dithiocarbamate conjugates as potential antifungal agents against *Candida albicans*†

 Henna Amin,^{‡ac} Hadiya Amin Kantroo,^{‡bc} Mohamad Mosa Mubarak,^{bc} Showkat Ahmad Bhat,^{ibac} Zahoor Ahmad^{*bc} and Khursheed Ahmad Bhat^{ID*ac}

Diverse betulinic acid–dithiocarbamate conjugates were designed and synthesized *via* a two-step reaction at room temperature. Among the fourteen dithiocarbamate analogs of betulinic acid, DTC2 demonstrated the best antifungal activity against *Candida albicans*, with a minimum inhibitory concentration (MIC) of 4 $\mu\text{g mL}^{-1}$, achieving 99% fungicidal activity at the same concentration. These compounds were found to be ineffective against common Gram-negative and Gram-positive pathogens, suggesting their specificity to fungi. Furthermore, DTC2 exhibited synergistic effects with the antifungal drugs fluconazole and nystatin, resulting in a significant decrease in MIC by 64 and 16 folds, respectively, when co-administered. Notably, the molecule also hindered hyphae formation in *Candida albicans*, thereby reducing its pathogenicity. Furthermore, it displayed time- and concentration-dependent kill kinetics, sterilizing *C. albicans* within 8 hours at 8 \times MIC. Additionally, DTC2 exhibits greater efficacy against β -carbonic anhydrase with better docking scores and binding patterns than ethoxzolamide, a well-known inhibitor of β -carbonic anhydrase.

 Received 11th July 2024
 Accepted 3rd November 2024

DOI: 10.1039/d4ra05020g

rsc.li/rsc-advances

Introduction

A recent increase in the prevalence of fungal infections has necessitated the need for the development of new antifungals. Fungal pathogens are responsible for approximately 13 million infections worldwide,¹ accounting for an increasing mortality rate of around 1.5 million deaths annually.² The number is expected to increase in the coming years due to the lack of potent therapeutics, shifts in the epidemiology of invasive fungal infections (IFI), a sharp surge in IFI among immunocompromised patients and the emergence of multidrug resistance.³ Candidiasis, a fungal infection, is caused by the overgrowth of *Candida*, predominantly *Candida albicans*, which is a leading causative agent responsible for approximately 70% of systemic candidiasis and mucosal infections. In normal individuals, it is usually found in association with microbial flora, while in the case of immunocompromised patients, it is an opportunistic pathogen. In the current scenario, three categories of drugs, *i.e.*, azoles (synthetic), polyenes and echinocandins (natural

product), are used in the treatment of mycosis.⁴ The ability of *Candida albicans* to switch between different morphological forms, along with its resemblance to the human metabolic pathways, complicates the treatment of infections caused by this pathogen.⁵ This problem can be addressed by exploring novel antifungal agents and identifying the drug targets. Nature has consistently come to the aid of humans, as it harbours a vast array of chemically diverse molecules, known as natural products that exhibit potent biological activity. Griseofulvin, a polyketide, was the first natural product-based antifungal used systemically for the treatment of skin and nail infections.⁶ Pentacyclic triterpenes are the class of natural products that demonstrate a wide range of biological activity, such as

^aBioorganic Chemistry Division, Indian Institute of Integrative Medicine (CSIR), Srinagar, J&K, 190005, India. E-mail: kabhat@iiim.res.in


^bClinical Microbiology and PK-PD Division, CSIR Indian Institute of Integrative Medicine, Srinagar, J&K, 190005, India. E-mail: zap@iiim.res.in

^cAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra05020g>

‡ Authors with equal contribution.

(a) Some triterpene based antifungals and betulinic acid



(b) Some Dithiocarbamate bearing antifungal drugs




Fig. 1 (a) Structures of betulinic acid, antifungal triterpenes and (b) dithiocarbamate antifungal compounds.



anticancer,⁷ antiviral, antioxidant, and anti-inflammatory.⁸ Fig. 1a depicts ibrexafungerp, a natural triterpene, presently undergoing phase III clinical trials for treating various fungal vulvovaginal conditions.⁹ Additionally, enfumafungin, another triterpenoid glycoside extracted from *Hormonema carpetanum*, exhibits potent antifungal properties.¹⁰ Betulinic acid (3-beta-hydroxy-lup-20(29)-en-28-oic acid), a pentacyclic lupane-type triterpenoid, is widely distributed throughout the plant kingdom. It is known for its anticancer,¹¹ anti-inflammatory,¹² antidiabetic,¹³ anti-HIV,¹⁴ antimalarial,¹⁵ and antidepressant properties.¹⁶ The modifications are usually carried out at C-3 hydroxyl, C-19 alkene and C-23 hydroxyl of betulinic acid to generate various functional derivatives.¹⁷ Dithiocarbamates are a group of sulphur containing compounds having predominant applications in the field of bioorganic and medicinal chemistry.¹⁸ The synthesis is usually carried out by reacting carbon disulphide and amine (primary or secondary) in the presence of electrophiles, such as imines, transition metals, epoxides, and alkyl halides. Dithiocarbamates possess potent antimicrobial properties due to the presence of an electron donating sulphur atom that forms chelates with positively charged metal, delocalizing electrons over the whole chelate ring. The sulphur atom reduces the polarity of the binding metal and thus increases the drug permeability into the microbial system.¹⁹ In certain cases, a hydrogen bond is usually formed between the binding site of the microbe and the $-N-(S)SH$ group present in dithiocarbamates, causing an interruption in the normal physiology of the microbial system.²⁰ It is an important scaffold in various antifungal drugs (Fig. 1b), such as sulbentine, rhodanine and brassinin.^{21–23}

Considering the importance of triterpene and dithiocarbamate moieties as antifungals, we synthesized dithiocarbamate conjugates of betulinic acid to explore their antifungal activity against *Candida albicans*. Interestingly, among all the synthesized molecules, it was observed that **DTC2** is highly potent against *Candida albicans*. Moreover, it showed synergism with the known antifungals (fluconazole and nystatin). A significant decrease in the MIC of these drugs was observed when taken in combination with **DTC2**. The docking studies further confirmed that **DTC2** exhibited greater efficacy with a greater docking score and binding patterns against β -carbonic anhydrase than ethoxazolamide.

Results and discussion

Structural modification of bioactive natural products for enhancing pharmacological activities is an important research area in drug discovery.²⁴ Herein, we design the structural modification of betulinic acid to fine tune its antifungal potential. Dithiocarbamates show diverse biological activities, such as anticancer, antifungal, antibacterial, antitubercular, antihyperglycemic, and anti-inflammatory. Therefore, betulinic acid (**BA**) was modified to produce the dithiocarbamate conjugates. Betulinic acid was first esterified to obtain **BE**, followed by a reaction with CS_2 and various secondary amines in the presence of K_2HPO_4 to obtain the desired derivatives. The reaction is facile with excellent yield. The products were identified using

NMR and MS spectral data. The formation of intermediate compound **BE** is easily identified from the appearance of two new peaks at δ 63.3 and δ 27.5 in DEPT-NMR due to OCH_2 and CH_2Br , respectively. The molecular ion peak at m/z 562.30 further confirmed the formation of **BE**. The formation of the dithiocarbamate derivative **DTC1** was ascertained from the diagnostic resonance peak at δ 194.4 due to the carbon-sulphur double bond. **DTC1** was finally confirmed by its molecular ion peak at m/z 644.41 $[M + H]^+$. Diverse dithiocarbamate derivatives of **BA** were prepared to study the effects of different substituents on antifungal activity. Different secondary amines, such as substituted piperidines, piperazines, pyrrolidines, thiomorpholine and morpholine were used to furnish the final compounds.

All the compounds were later screened for antimicrobial activity against *Candida albicans* (MTCC 183), *Escherichia coli* (MTCC 118) and *Staphylococcus aureus* (MTCC 737).

In vitro activity of compounds against *C. albicans*

All the derivatives of betulinic acid (**DTC1–14**) were screened for antimicrobial activity against *C. Albicans* (Table 1). The results showed that most of the compounds possess moderate activity with an MIC of 64 or 128 $\mu g mL^{-1}$. Only two compounds (**DTC11** and **DTC13**) possess slightly better activity with an MIC of 32 $\mu g mL^{-1}$. However, **DTC2** displayed the best antifungal activity with an MIC value of 4 $\mu g mL^{-1}$. The control drugs, fluconazole and nystatin, possess MIC values of 2 $\mu g mL^{-1}$ and 4 $\mu g mL^{-1}$, respectively.

All the analogs except **DTC2**, **DTC11** and **DTC13** possess antifungal activity against *C. albicans* similar to that of parent molecule **BA**. Therefore, it can be inferred that the electronic structure of amine is essential for the enhanced activity of particular dithiocarbamate analogs. Furthermore, the cyclopropyl piperazine and bromo phenyl piperazine moieties of the carbamate group impart better activity to **DTC11** and **DTC13**, respectively.

All the analogs except for **DTC2** bear a six-membered heterocyclic ring, while **DTC2** has five-membered pyrrolidine as part of the carbamate group. Thus, it clearly shows that pyrrolidine bearing carbamate is essential for activity.

Table 1 MIC values of the synthesized compounds measured in $\mu g mL^{-1}$. MIC values of controls: fluconazole (0.039–20 $\mu g mL^{-1}$) and nystatin (0.039–20 $\mu g mL^{-1}$) were 2 $\mu g mL^{-1}$ and 4 $\mu g mL^{-1}$, respectively, against *C. albicans*

| S. no. | Compound | MIC* ($\mu g mL^{-1}$) | S. no. | Compound | MIC* ($\mu g mL^{-1}$) |
|--------|-------------|--------------------------|--------|--------------|--------------------------|
| 1 | BA | 64 | 9 | DTC8 | 64 |
| 2 | DTC1 | 128 | 10 | DTC9 | 64 |
| 3 | DTC2 | 4 | 11 | DTC10 | 64 |
| 4 | DTC3 | 128 | 12 | DTC11 | 32 |
| 5 | DTC4 | 64 | 13 | DTC12 | 64 |
| 6 | DTC5 | 64 | 14 | DTC13 | 32 |
| 7 | DTC6 | 64 | 15 | DTC14 | 64 |
| 8 | DTC7 | 64 | | | |



Activity against other pathogens (Gram-positive and Gram-negative bacteria)

After identifying the promising antifungal activity of **DTC2** against *C. albicans*, we screened compounds (**DTC**, **DTC1-14**) against *E. coli* (Gram-negative) and *S. aureus* (Gram-positive) to explore their antibacterial potential. The results (Table 2) revealed that all the derivatives, including the parent compound, possess moderate activity against both Gram-positive and Gram-negative bacteria, with MIC values ranging from 64 to 128 $\mu\text{g mL}^{-1}$.

Evaluation of full spectrum antifungal activity of this series of compounds

This series of compounds was evaluated against *Candida glabrata* and *Aspergillus* species, including *Aspergillus niger*, *Aspergillus flavus*, and *Aspergillus fumigatus*. The compounds exhibited moderate activities in the range of 64–128 $\mu\text{g mL}^{-1}$ against these fungal strains.

Activity against other pathogens (Gram-positive and Gram-negative bacteria)

After identifying the promising antifungal activity of **DTC2** against *C. albicans*, we screened compounds (**DTC**, **DTC1-14**) against *E. coli* (Gram-negative) and *S. aureus* (Gram-positive) to explore their antibacterial potential. The results (Table 2) revealed that all the derivatives, including the parent compound, possess moderate activity against both Gram-positive and Gram-negative bacteria, with MIC values ranging from 64 to 128 $\mu\text{g mL}^{-1}$.

Minimum fungicidal concentration (MFC) of the lead compound

After confirming the promising fungistatic activity of **DTC2**, we delved into its fungicidal properties. Interestingly, the MFC value for **DTC2** precisely matched its MIC, establishing an MIC to MFC ratio of 1 (<4). This indicates that **DTC2** is fungicidal²⁵ and can eradicate 99% of the pathogen at 4 $\mu\text{g mL}^{-1}$. In comparison, controls fluconazole and nystatin exhibited an MFC to MIC ratio of 2 (Table 3), indicating their fungicidal nature.

Table 3 MFC values for **DTC2** and controls fluconazole and nystatin against *C. albicans*

| S. no. | Compound | MFC ($\mu\text{g mL}^{-1}$) | MFC/MIC ratio |
|--------|-------------|-------------------------------|---------------|
| 1 | DTC2 | 4 | 1 |
| 2 | Fluconazole | 4 | 2 |
| 3 | Nystatin | 8 | 2 |

Hyphal morphogenesis analysis

As hyphae contribute to the pathogenicity of *C. albicans*, we investigated the impact of the lead compound on hyphal formation using fluorescence microscopy. Observations revealed diminished filamentation in *C. albicans* images with escalating concentrations of **DTC2** akin to the fluconazole-treated group (Fig. 2). This suggests that the compound effectively mitigates the pathogenicity of *C. albicans*. Control wells displayed robust hyphal growth, while no culture was found in MIC wells. In wells at MIC and sub-MIC concentrations, inhibited hyphae formation is demonstrated with increasing drug concentration, which are indicated by red arrows.

Evaluation of lead compounds with standard antifungal drugs

DTC2 was assessed in various combinations with established antifungals, fluconazole and nystatin, using the checkerboard microdilution assay. A notable decrease in the MIC of **DTC2** was observed when combined with both fluconazole and nystatin. Specifically, in combination with fluconazole, the MIC of **DTC2** decreased 64-fold, while the MIC of fluconazole decreased by 16-fold, resulting in a ΣFIC value of 0.0781 (<0.5), which indicates synergism (entry 1 in Table 4). Similarly, when combined with nystatin, the MIC of **DTC2** decreased by 64-fold, and the MIC of nystatin decreased by 32-fold, yielding a ΣFIC value of 0.0468 (<0.5), which also indicates synergism (entry 2 in Table 4).

Time kill kinetics of **DTC2** against *C. albicans*

We conducted kill kinetics studies on **DTC2**, revealing intriguing results. At both the MIC and 2 \times MIC, the drug exhibited a 2-log reduction in microbial count by the 8th hour and a 4-log reduction by the 16th hour, effectively sterilizing the

Table 2 MIC values of the synthesized compounds measured in $\mu\text{g mL}^{-1}$. MIC values of controls: Ciprofloxacin (0.039–20 $\mu\text{g mL}^{-1}$) and Streptomycin (0.039–20 $\mu\text{g mL}^{-1}$) were 1.25 $\mu\text{g mL}^{-1}$ and 2.5 $\mu\text{g mL}^{-1}$, respectively

| S. no. | Compound | MIC [#] ($\mu\text{g mL}^{-1}$) | | S. no. | Compound | MIC [#] ($\mu\text{g mL}^{-1}$) | |
|--------|-------------|--|------------------|--------|---------------|--|------------------|
| | | <i>E. coli</i> | <i>S. aureus</i> | | | <i>E. coli</i> | <i>S. aureus</i> |
| 1 | BA | 128 | 128 | 10 | DTC9 | 128 | 128 |
| 2 | DTC1 | 128 | 128 | 11 | DTC10 | 64 | 128 |
| 3 | DTC2 | 128 | 128 | 12 | DTC11 | 128 | 128 |
| 4 | DTC3 | 128 | 64 | 13 | DTC12 | 128 | 128 |
| 5 | DTC4 | 64 | 128 | 14 | DTC13 | 128 | 128 |
| 6 | DTC5 | 128 | 128 | 15 | DTC14 | 128 | 128 |
| 7 | DTC6 | 128 | 128 | 16 | Ciprofloxacin | 1.25 | 1.25 |
| 8 | DTC7 | 128 | 64 | 17 | Streptomycin | 2.5 | 2.5 |
| 9 | DTC8 | 128 | 128 | | | | |






Fig. 2 Hyphae inhibition in *C. albicans* by (A) DTC2 and (B) fluconazole.

Kill Kinetics of DTC-2 against *C. albicans*




Fig. 3 Impact of DTC2 on *C. albicans* examined over 24 hours with concentrations: MIC (magenta), 2× MIC (violet), 4× MIC (green), and 8× MIC (maroon).

pathogen by the 24th hour. Conversely, at 4× MIC, complete sterilization was achieved by the 12th hour, while at 8× MIC, it occurred as early as the 8th hour (Fig. 3). These findings underscore DTC2's time and concentration-dependent bactericidal activity against *C. albicans*, characterized by a progressive decrease in log values with increasing time and concentration. Understanding time-kill kinetics is crucial because it provides insights into how the antimicrobial impact on microbial elimination or growth inhibition changes over time. Such knowledge is essential for optimizing dosage regimens in therapeutic drug monitoring, aiding in determining the optimal timing and frequency of drug administration to maintain therapeutic levels throughout the dosing interval.²⁶

Cytotoxicity assay

The cytotoxicity of the most potent antifungal molecule, *i.e.*, DTC2, was evaluated on HEK-293 cells using an MTT assay at concentrations ranging from 5 μM to 500 μM , and cell viability was measured after 24 hours of incubation. At higher concentrations, a notable reduction in cell viability was observed; at 50 μM , cell viability decreased by 32.26%. In contrast, at lower concentrations, especially those matching MIC concentrations, magnificent cell viabilities of 64.3% for 10 μM and 73.69% for 5 μM (Fig. 4) were observed. These results indicate that DTC2

Table 4 Effect of DTC2 in combination with fluconazole (FLU) and nystatin (NYS) against *C. albicans*

| S. no. | Drug/drug combination | MIC ($\mu\text{g mL}^{-1}$) | | FIC ($\mu\text{g mL}^{-1}$) | ΣFIC | Remarks |
|--------|-----------------------|-------------------------------|-------------|-------------------------------|--------------------|-----------|
| | | Alone | Combination | | | |
| 1 | Fluconazole | 2 | 0.125 | 0.0625 | 0.0781 | Synergism |
| | DTC2 | 4 | 0.0625 | 0.0156 | | |
| 2 | Nystatin | 4 | 0.125 | 0.03125 | 0.0468 | Synergism |
| | DTC2 | 4 | 0.0625 | 0.0156 | | |






Fig. 4 Cell viability percentage of HEK-298 cell lines on exposure to DTC2 at concentrations 5 μM, 10 μM, 50 μM, 100 μM, 250 μM, and 500 μM.

exhibits significantly lower toxicity near its antifungal concentrations, maintaining over 70% cell viability.

Molecular docking and mechanistic potential of DTC2

A docking study was performed for lead molecule **DTC2** against β-carbonic anhydrase of *C. albicans*, an enzyme crucial for the pathogen's survival under varying CO₂ concentrations. The results showed that **DTC2** exhibited a strong binding affinity for β-carbonic anhydrase, with a docking score of -384.47 kJ mol⁻¹. It is worth mentioning that **DTC2** significantly outperformed a well-known inhibitor of carbonic anhydrase, ethoxzolamide, with only a docking score of




Fig. 5 Binding of DTC2 to β-carbonic anhydrase of *C. albicans*, a key enzyme that helps in the survival of this pathogen under different CO₂ concentrations.

-216.62 kJ mol⁻¹. The compound interacts with several residues, such as glutamine (A:230), phenylalanine (A:233), and arginine (A:196), with an extensive network of pi-alkyl and hydrogen bonds. The hydrogen bond with glutamine (A:230) and additional pi-alkyl interactions with arginine and histidine indicate a more hydrophobic binding pocket. The control, ethoxzolamide, shows hydrogen bonding (conventional and carbon-hydrogen bonds) with asparagine (A:151, C:151), glycine (C:147, A:148), and lysine (A:145) while exhibiting pi-anion interactions with asparagine (A:151) and pi-alkyl interactions with leucine (A:152) and valine (C:149). This indicates a binding pocket with both hydrophilic and hydrophobic interactions. Overall, the **DTC2** shows a more robust network of hydrophobic interactions compared to ethoxzolamide, suggesting that it may have a more significant binding affinity for hydrophobic regions of the substrate (Fig. 5). Our study aligns with previous studies, showing that betulinic acid is ineffective against *C. albicans*. However, modifications at the 28-C position of the compound demonstrated improved activity against *C. albicans*.²⁷ Similarly, in our study, the addition of a dithiocarbamate group at the C-28 position enhanced the activity, likely by helping the compound reach the target.

Experimental section

General information

All the necessary reagents and solvents were purchased from Sigma-Aldrich and TCI. UV cabinet (camag) was used to visualise spots on TLC. All the products were purified using silica gel (60–120) column chromatography. ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ using 400 and 125 MHz NMR spectrometers, respectively. Chemical shifts of ¹H and ¹³C NMR were expressed in parts per million (ppm).

Experimental procedures

Procedure for isolation of betulinic acid from *Platanus orientalis*. The dry bark of *Platanus orientalis* was taken and chopped into small pieces and meshed to powder form. The powdered plant material was then put into a 2.5 L conical flask containing chloroform and was kept for 24 hours. The mother liquor was then filtered through Whatman filter paper and consequently concentrated under reduced pressure. The concentrate was further washed with hexane to remove some nonpolar impurities. The extract thus obtained was purified using silica gel column chromatography, and pure betulinic acid molecules (**BA**) (12 grams) were isolated with increasing polarity of hexane:ethyl acetate solvent system (Fig. 6).

Procedure for the synthesis of BE. To a 50 mL round bottom flask containing 20 mL DMF, betulinic acid (1 g, 2.1 mmol) and potassium carbonate (290.2 mg, 2.1 mmol) were added to 1,2-dibromoethane (0.78 g, 4.2 mmol). The mixture was stirred at 40 °C for 6–8 hours. The progress of the reaction was monitored using TLC. After the completion of the reaction, ice cold water was added to the reaction mixture and extracted with EtOAc. The process was repeated thrice, and the organic layers were pooled and concentrated under a vacuum to yield the residue.







Fig. 6 Procedure for the isolation of betulinic acid.

The residue thus obtained was purified using silica gel column chromatography (mesh size 60–120) and hexane–EtOAc as an eluent to obtain the desired product (**BE**) with 80% yield (0.94 grams).

Synthesis of dithiocarbamate conjugates of betulinic acid. A solution of secondary amine (0.12 mmol, 1.2 eq.) (Scheme 1) in DMF (3 mL) was added CS_2 (0.12 mmol, 1.2 eq.) and K_2HPO_4 (0.15 mmol, 1.5 eq.) in a 25 mL round bottom flask. The reaction mixture was stirred at room temperature for 30 minutes, followed by the addition of **BE** (0.1 mmol, 1.0 eq.). The reaction mixture was further stirred for 4–5 hours. The progress of the reaction was monitored using TLC. After completion of the reaction, ice cold water was added to the reaction mixture and extracted with EtOAc. The organic layer was dried using sodium sulphate, concentrated over reduced pressure and purified through silica gel column chromatography (mesh size 60–120)



Scheme 1 Synthesis of various dithiocarbamate conjugates of betulinic acid.

and hexane–EtOAc as eluent to obtain the desired products, **DTC1–DTC14**.

Chemicals and reagents for the determination of antifungal and antibacterial activity of betulinic acid analogs (DTC1–DTC14). Sabouraud Dextrose Agar (SDA), Sabouraud Dextrose Broth (SDB), Muller Hinton Broth (MHB), and Nutrient Agar (NA) were procured from HiMedia, while RPMI-1640 was obtained from Sigma-Aldrich, and 96 well plates were from Tarrsons. All the test samples, parent compounds as well as reference antifungal agents (fluconazole (FLU) and nystatin (NYS)) and antibacterial agents (Ciprofloxacin (CIP) and Streptomycin (STR)) were prepared as 10 mg mL^{-1} stock solutions in dimethyl sulfoxide (DMSO) and stored at $4 \text{ }^\circ\text{C}$.

Fungal and bacterial strains. The fungal strain *Candida albicans* (MTCC 183), *Candida glabrata* (MTCC 3019), *Aspergillus niger* (MTCC 281), *Aspergillus fumigatus* (MTCC 8248), *Aspergillus flavus* (MTCC 3783), bacterial strains *Escherichia coli* (MTCC 118) and *Staphylococcus aureus* (MTCC 737) were obtained from CSIR-IMTech and maintained at $-80 \text{ }^\circ\text{C}$. For each experiment, the strains were thawed and cultured in the respective broths (SDB for the fungal strain and MHB for the bacterial strains) until they reached an optical density (OD 600) of 0.4 to 0.5.

Determination of minimum inhibitory concentration (MIC). MIC was determined using the broth micro-dilution method, following established procedures for fungi²⁸ and bacteria,²⁹ respectively. In brief, for fungi, RPMI medium with serial two-fold concentrations ranging from 0.25 to $128.00 \text{ } \mu\text{g mL}^{-1}$ of compounds **DTC1–DTC14** was used. Approximately 1×10^3 cells of *Candida* species and 1×10^4 cells of *Aspergillus* species were inoculated in individual wells of a 96-well plate. Control wells contained fluconazole, nystatin, and Itraconazole at concentrations ranging from 0.078 to $20 \text{ } \mu\text{g mL}^{-1}$. For bacteria, MHB containing serial two-fold concentrations from 0.25 to $128.00 \text{ } \mu\text{g mL}^{-1}$ of **DTC1** to **DTC14** were separately inoculated with $\sim 1 \times 10^5$ cells of *Escherichia coli* and *Staphylococcus aureus* in a 96-well plate. Control wells contained Ciprofloxacin (CIP) and Streptomycin (STR) at concentrations ranging from 0.078 to $20 \text{ } \mu\text{g mL}^{-1}$. After 24 hours of incubation at $37 \text{ }^\circ\text{C}$, the plates were inspected for visible growth.

Determination of minimum fungicidal concentration (MFC) for lead compound. MFC was assessed following MIC determination, as done previously.³⁰ Wells, showing no growth at MIC and above MIC (2 \times , 4 \times , 8 \times , and 16 \times MIC) of **DTC2**, fluconazole and nystatin, were plated onto Sabouraud dextrose agar. Incubation at $37 \text{ }^\circ\text{C}$ for 24 hours preceded colony counting to determine MFC, which is crucial for evaluating antifungal efficacy. MFC was the concentration at which 99% killing of pathogens was observed. The MIC/MFC ratio was computed to discern the fungistatic or fungicidal nature of **DTC2**.

C. albicans morphogenesis analysis. *C. albicans* cells were exposed to **DTC2** at MIC and sub-MIC concentrations (MIC/2, MIC/4) and incubated for 24 hours at $37 \text{ }^\circ\text{C}$ in a 12-well plate. Following this incubation, a detailed microscopic examination of the plate was conducted to evaluate the impact of **DTC2** treatment specifically on hyphae formation within the *Candida albicans* cells (the imaging system model used was CH30RF200 from Olympus Optical Co. Ltd, Shinjuku, Tokyo, Japan. It was



coupled with a Magnus camera (Magcam-DC, Central Honsho, Japan). The images showcased were taken at a magnification of 40 \times). This approach aimed to elucidate the antifungal effects of **DTC2** on the morphological characteristics and growth patterns of the treated *C. albicans* cells.³¹

Drug–drug interaction with known antibiotics. To elucidate the interaction dynamics and efficacy of **DTC2** with established antifungal agents (fluconazole and nystatin), a Checkerboard Micro Dilution Assay was conducted, as done previously.³² The assay spanned a range covering their MICs. In 96-well plates, **DTC2** underwent horizontal serial dilution, while the established antifungal agent fluconazole/nystatin underwent vertical dilution, creating a checkerboard configuration of the combined concentrations. Each well received an inoculum of *C. albicans*, with a log₁₀ CFU value of 103. Following a 24 hour incubation at 37 °C, the Fractional Inhibitory Concentration Index (FICI) was determined (FICI = FICIA + FICIB). The \sum FIC, obtained by adding the FIC of **DTC2** to that of FLU/NYS, was utilized to assess synergy (≤ 0.5), additivity or no interaction (0.5–4), or antagonism (≥ 4) in the combined concentrations of **DTC2** and fluconazole/nystatin.

Time kill kinetics. To investigate the fungicidal mechanism of **DTC2**, a time-kill kinetics assay was conducted following CLSI guidelines.³³ Tubes containing SDB with varying **DTC2** concentrations (1 \times MIC, 2 \times MIC, 4 \times MIC, and 8 \times MIC) were inoculated with *C. albicans* at a density of 10⁶ cells per mL. Incubation at 37 °C for 24 hours was followed by viability checks at 0, 2, 4, 8, 12, 16, and 24 hours. Serial dilutions in normal saline solution (NSS) were plated on SDA, and after subsequent 24 hour incubation at 37 °C, colony counts were determined.³⁴ Log₁₀ reductions were calculated for each time interval, and a CFU *versus* time graph was generated using GraphPad Prism 9.0. Three independent experiments were performed, and the mean data were plotted.

Cytotoxicity assay. The cytotoxicity of the lead compound, **DTC-2**, was evaluated using the MTT assay on HEK-293 cells (human embryonic kidney cells). Cells in their logarithmic growth phase were harvested, counted, and seeded at a density of 10⁴ cells per well in 100 μ L of culture medium in a 96-well microtiter plate. After overnight incubation at 37 °C with 5% CO₂ to allow cell attachment, the cells were exposed to different concentrations of **DTC-2** (5, 10, 50, 100, 250, and 500 μ M) in triplicate. The treated cells were incubated for an additional 24 hours under the same conditions. MTT solution (20 μ L) was then added to each well, and the plates were shaken at 150 rpm for 5 minutes to ensure thorough mixing. After 1–5 hours of incubation at 37 °C with 5% CO₂ to allow the MTT to be metabolized, the media was removed, and 200 μ L of DMSO was added to dissolve the formazan crystals. Absorbance at 560 nm was measured using an ELISA plate reader, and cell viability percentages were calculated.³⁵

Molecular docking. The crystal structure of β -carbonic anhydrase was retrieved from the RCSB PDB database, while the structure of ethoxzolamide was obtained from PubChem. 3D models of **DTC-2** and fluconazole were generated using ChemBioDraw3D Pro and subsequently energy-minimized in PDB format. Molecular docking of β -carbonic anhydrase with the

ligands **DTC-2** and ethoxzolamide was conducted separately using Hex 8.0, with a 0.6 Å grid applied across all ligand–receptor coordinates. Docking parameters, including translational steps, protein flips, and twist range, were set to 360°. The resulting docked models were analyzed using Discovery Studio Visualizer to examine the 3D structures and visualize the binding interactions.³⁶

Analytical data

BE: 2-Bromoethyl 9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-carboxylate. The product was purified by column chromatography using hexane : EtOAc (94 : 6) to afford **BE** as a pale white solid, displayed molecular ion peak at m/z 562.30 [M]⁺ in ESIMS, corresponding to molecular formula C₃₂H₅₁BrO₃. ¹H NMR (400 MHz, CDCl₃) δ 4.67 (s, 1H), 4.60–4.50 (m, 1H), 4.33 (dd, J = 10.9, 5.8 Hz, 2H), 3.47 (t, J = 5.9 Hz, 2H), 3.12 (dd, J = 11.2, 5.0 Hz, 1H), 3.07–2.85 (m, 1H), 2.25–2.19 (m, 1H), 2.12 (td, J = 12.7, 3.6 Hz, 1H), 1.89–1.80 (m, 2H), 1.72 (s, 1H), 1.65 (d, J = 2.4 Hz, 1H), 1.62 (s, 3H), 1.58 (d, J = 5.2 Hz, 1H), 1.53 (dd, J = 7.6, 3.9 Hz, 2H), 1.48–1.40 (m, 2H), 1.40–1.32 (m, 5H), 1.30 (s, 2H), 1.18 (s, 3H), 1.12–1.07 (m, 1H), 0.96 (d, J = 12.4 Hz, 1H), 0.90 (d, J = 2.6 Hz, 6H), 0.85 (s, 3H), 0.82 (d, J = 4.6 Hz, 1H), 0.75 (s, 3H), 0.68 (s, 3H), 0.61 (d, J = 9.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 175.76, 150.46, 109.70, 79.02, 63.35, 56.69, 55.34, 50.55, 49.42, 46.96, 42.41, 40.74, 38.86, 38.79, 38.34, 37.19, 37.01, 34.31, 32.07, 30.59, 29.68, 29.19, 27.99, 27.38, 25.53, 20.89, 19.38, 18.29, 16.15, 16.00, 15.37, 14.72.

DTC1: 2-((piperidine-1-carbonothioyl)thio)ethyl-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-carboxylate. The product was purified by column chromatography using hexane : EtOAc (94 : 6) to afford **DTC1** as a pale yellow solid, displaying a molecular ion peak at m/z 644.41 [M + H]⁺ in ESIMS, consistent with molecular formula C₃₈H₆₁NO₃S₂. ¹H NMR (400 MHz, CDCl₃) δ 4.74 (s, 1H), 4.61 (s, 1H), 4.36 (dt, J = 11.2, 5.7 Hz, 4H), 3.66 (t, J = 6.2 Hz, 2H), 3.20 (dd, J = 11.2, 4.9 Hz, 1H), 3.06–2.98 (m, 1H), 2.33–2.24 (m, 1H), 2.20 (td, J = 12.6, 3.5 Hz, 1H), 2.00–1.86 (m, 2H), 1.73 (s, 5H), 1.70 (s, 3H), 1.66–1.57 (m, 5H), 1.54–1.49 (m, 2H), 1.40 (dd, J = 9.6, 6.2 Hz, 8H), 1.28 (d, J = 9.3 Hz, 3H), 1.19–1.14 (m, 1H), 1.08–1.02 (m, 1H), 0.98 (s, 6H), 0.93 (s, 3H), 0.88 (s, 2H), 0.82 (s, 3H), 0.77 (s, 3H), 0.69 (d, J = 9.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 194.46, 175.92, 150.61, 109.59, 78.98, 62.07, 56.59, 55.34, 53.22, 51.34, 50.54, 49.42, 46.99, 42.42, 40.73, 38.86, 38.72, 38.34, 37.18, 37.03, 35.87, 34.33, 32.14, 30.65, 29.68, 27.99, 27.39, 26.05, 25.55, 25.41, 24.30, 20.89, 19.38, 18.28, 16.15, 16.07, 15.38, 14.72.

DTC2: 2-((pyrrolidine-1-carbonothioyl)thio)ethyl 9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysen-3a-carboxylate. The product was purified by column chromatography using hexane : EtOAc (94 : 6) to afford **DTC2** as a white solid, which displayed a molecular ion peak at m/z 630.39 [M + H]⁺ in ESIMS, corresponding to molecular formula C₃₇H₅₉NO₃S₂. ¹H NMR (400 MHz, CDCl₃) δ 4.74 (s, 1H), 4.61 (s, 1H), 4.35 (dt, J = 11.4, 6.2 Hz, 4H), 3.91 (s, 2H), 3.66 (t, J = 6.2 Hz, 2H), 3.20 (dd, J = 11.2, 4.9 Hz, 1H), 3.10–



2.98 (m, 1H), 2.44–2.15 (m, 2H), 1.95–1.89 (m, 2H), 1.66 (dt, $J = 11.5, 9.3$ Hz, 16H), 1.47–1.33 (m, 8H), 1.27 (s, 3H), 1.20–1.13 (m, 1H), 0.98 (s, 6H), 0.93 (s, 3H), 0.82 (s, 3H), 0.77 (s, 3H), 0.69 (d, $J = 9.2$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 194.46, 175.94, 150.69, 109.59, 79.16, 62.07, 56.59, 55.34, 50.54, 49.42, 47.00, 42.42, 40.73, 38.86, 38.72, 38.34, 37.18, 37.03, 35.87, 34.33, 32.15, 30.65, 29.68, 27.99, 27.40, 25.55, 24.30, 20.89, 19.38, 18.28, 16.14, 16.07, 15.37, 14.72.

Conclusions

In summary, dithiocarbamate derivatives of betulinic acid were prepared *via* a two-step reaction procedure. The method is the expeditious furnishing of products with high yields. Among all the synthesised analogs, **DTC2** has emerged as the most potent antifungal derivative, displaying robust activity against *C. albicans* with an MIC and MFC of $4 \mu\text{g mL}^{-1}$. It effectively suppresses hyphal growth in a concentration-dependent manner, thereby mitigating pathogenesis. Moreover, **DTC2** exhibits synergistic activity, surpassing the efficacy of individual drugs. Additionally, it demonstrates kill kinetics influenced by both time and concentration, achieving complete sterilization of *C. albicans* culture within just 8 hours at 8 times the MIC. Furthermore, **DTC-2** exhibits greater efficacy against β -carbonic anhydrase with better docking scores and binding patterns than ethoxazolamide, a well-known inhibitor of β -carbonic anhydrase.

Data availability

The data supporting this article are included in the ESI.†

Author contributions

Henna Amin and Hadiya Amin Kantroo have contributed equally in this work.

Conflicts of interest

The authors declare that they have no known competing financial interest or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

H. Amin and H. A. Kantroo thank ICMR and UGC for providing fellowship. We also thank SERB-DST Govt of India (No. CRG/2022/001920) and CSIR (HCP-0037). ZA is thankful to funding agencies; ICMR, DBT, and DST. Institutional publication No. CSIR-IIIM/IPR/00830.

References

- 1 F. Bongomin, S. Gago, R. O. Oladele and D. W. Denning, *J. Fungi*, 2017, **3**, 57.
- 2 E. Rayens and K. A. Norris, *Open Forum Infect. Dis.*, 2022, **9**(1), ofab593.

- 3 N. P. Wiederhold, *Infect. Drug Resist.*, 2017, **10**, 249–259.
- 4 M. Oura, T. H. Sternberg and E. T. Wright, *Antibiot. Annu.*, 1955, **3**, 566–573.
- 5 Y. Zhang and R. Rao, *Curr. Protein Pept. Sci.*, 2012, **13**, 134–140.
- 6 Y.-B. Bai, Y.-Q. Gao, X.-D. Nie, T. Tuong, L. Ding and J.-M. Gao, *J. Agric. Food Chem.*, 2019, **67**, 6125–6132.
- 7 K. T. Liby, M. M. Yore and M. B. Sporn, *Nat. Rev. Cancer*, 2007, **7**, 357–369.
- 8 H. Li, J. Sun, S. Xiao, L. Zhang and D. Zhou, *J. Med. Chem.*, 2020, **63**, 15371–15388.
- 9 M. Ghannoum, M. C. Arendrup, V. Chaturvedi, S. Lockhart, T. McCormick, S. Chaturvedi, E. Berkow, D. Juneja, B. Tarai, N. Azie, D. Angulo and T. Walsh, *Antibiotics*, 2020, **9**, 539.
- 10 J. Onishi, M. Meinz, J. Thompson, J. Curotto, S. Dreikorn, M. Rosenbach, C. Douglas, G. Abruzzo, A. Flattery, L. Kong, A. Cabello, F. Vicente, F. Pelaez, M. T. Diez, I. Martin, G. Bills, R. Giacobbe, A. Dombrowski, R. Schwartz, S. Morris, G. Harris, A. Tsipouras, K. Wilson and M. B. Kurtz, *Antimicrob. Agents Chemother.*, 2000, **44**, 368–377.
- 11 W. Jiang, X. Li, S. Dong and W. Zhou, *Biomed. Pharmacother.*, 2021, **142**, 111990.
- 12 J. F. Costa, J. M. Barbosa-Filho, G. L. Maia, E. T. Guimarães, C. S. Meira, R. Ribeiro-dos-Santos, L. C. de Carvalho and M. B. Soares, *Int. Immunopharmacol.*, 2014, **23**, 469–474.
- 13 S. J. Kim, H. Y. Quan, K. J. Jeong, D. Y. Kim, G. w. Kim, H. K. Jo and S. H. Chung, *J. Agric. Food Chem.*, 2014, **62**, 434–442.
- 14 T. Akihisa, J. Ogihara, J. Kato, K. Yasukawa, M. Ukiya, S. Yamanouchi and K. Oishi, *Lipids*, 2001, **36**, 507–512.
- 15 J. O. Olanlokun, P. O. Okoro, O. S. Lawal, O. Bodede, F. Olotu, T. O. Idowu, G. Prinsloo, M. E. Soliman and O. O. Olorunsogo, *J. Mol. Struct.*, 2021, **1239**, 130454.
- 16 D. G. Machado, M. P. Cunha, V. B. Neis, G. O. Balen, A. Colla, L. E. Bettio, A. Oliveira, F. L. Pazini, J. B. Dalmarco, E. L. Simionatto, M. G. Pizzolatti and A. L. Rodrigues, *Food Chem.*, 2013, **136**, 999–1005.
- 17 Y. Zhong, N. Liang, Y. Liu and M.-S. Cheng, *Chin. J. Nat. Med.*, 2021, **19**, 641–647.
- 18 L. Kaul, R. Süß, A. Zannettino and K. Richter, *iScience*, 2021, **24**, 102092.
- 19 J. O. Adeyemi and D. C. Onwudiwe, *Inorg. Chim. Acta*, 2020, **511**, 119809.
- 20 G. Manoussakis, C. Bolos, L. Ecatiniadou and C. Sarris, *Eur. J. Med. Chem.*, 1987, **22**, 421–425.
- 21 D. Chaturvedi, *Curr. Org. Chem.*, 2011, **15**, 1593–1624.
- 22 O. Guzel and A. Salman, *Bioorg. Med. Chem.*, 2006, **14**, 7804.
- 23 K. Chauhan, M. Sharma, P. Singh, V. Kumar, P. K. Shukla, M. I. Siddiqi and P. M. S. Chauhan, *MedChemComm*, 2012, **3**, 1104–1110.
- 24 S. Xiao, Z. Tian, Y. Wang, L. Si, L. Zhang and D. Zhou, *Med. Res. Rev.*, 2018, **38**, 951–976.
- 25 K. Q. Chi, Z. Y. Wei, K. S. Wang, J. Wu, W. Q. Chen, X. J. Jin and H. R. Piao, *Bioorg. Chem.*, 2017, **75**, 157–169.



Paper

- 26 F. L. Mayer, D. Wilson and B. Hube, *Virulence*, 2013, **4**, 119–128.
- 27 S. Haque, D. A. Nawrot, S. Alakurtti, L. Ghemtio, J. Yli-Kauhaluoma and P. Tammela, *PLoS One*, 2014, **9**, e102696.
- 28 E. J. Begg, M. L. Barclay and C. J. Kirkpatrick, *Br. J. Clin. Pharmacol.*, 1999, **47**, 23–30.
- 29 F. Hadacek and H. Greger, *Phytochem. Anal.*, 2000, **11**, 137–147.
- 30 J. Ali, M. M. Mubarak, C. Samuel, H. A. Kantroo, A. Malik, Z. Ahmad and V. Baskar, *J. Inorg. Biochem.*, 2022, **235**, 111909.
- 31 A. Espinel-Ingroff, A. Fothergill, J. Peter, M. G. Rinaldi and T. J. Walsh, *J. Clin. Microbiol.*, 2002, **40**, 3204–3208.
- 32 R. Kumpakha and D. M. Gordon, *J. Appl. Microbiol.*, 2022, **132**, 3038–3048.
- 33 P. Bellio, L. Fagnani, L. Nazzicone and G. Celenza, *MethodsX*, 2021, **8**, 101543.
- 34 Y. Öz, H. G. Özdemir, E. Gökbolat, N. Kiraz, M. Ilkit and S. Seyedmousavi, *Mycopathologia*, 2016, **181**, 225–233.
- 35 E. V. Sazonova, M. S. Chesnokov, B. Zhivotovsky and G. S. Kopeina, *Cell Death Discov.*, 2022, **8**, 417.
- 36 N. Kumar, A. Awasthi, A. Kumari, D. Sood, P. Jain, T. Singh, N. Sharma, A. Grover and R. Chandra, *J. Biomol. Struct. Dyn.*, 2022, **40**, 101–116.

